生物技术公司Blueprint Medicines Corporation（BPMC）今日盘中股价大涨5.06%，尽管公司公布的季度业绩显示亏损超出预期。这一涨幅引起了投资者的广泛关注。
根据公司最新发布的财报，截至3月31日的季度，Blueprint Medicines调整后每股亏损74美分，高于分析师平均预期的53美分亏损。然而，公司营收同比大幅增长55.5%，达到1.4941亿美元，虽略低于分析师预期的1.5545亿美元，但仍显示出强劲的增长势头。
尽管季度业绩未能达到华尔街预期，但投资者似乎更关注公司的长期发展前景。分析师对该公司保持积极态度，平均评级为"买入"，其中16个为"强烈买入"或"买入"，5个为"持有"，仅1个为"卖出"或"强烈卖出"。华尔街给予Blueprint Medicines未来12个月的目标价中位数为130.00美元，这可能也是支撑股价上涨的因素之一。公司在生物技术和医学研究领域的持续创新以及收入的快速增长，可能是投资者看好其未来发展的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.